Journal
PROTEOMICS
Volume 16, Issue 11-12, Pages 1718-1725Publisher
WILEY-BLACKWELL
DOI: 10.1002/pmic.201600036
Keywords
Acetretin; Interleukin-22; Living skin equivalent; MALDI-MSI; Psoriasis; Skin; Tissue engineering; Technology
Funding
- NC3Rs Grant [NC/L001896/1]
- NC3Rs [NC/L001896/1] Funding Source: UKRI
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) [NC/L001896/1] Funding Source: researchfish
Ask authors/readers for more resources
MALDI-MS Imaging is a novel label-free technique that can be used to visualize the changes in multiple mass responses following treatment. Following treatment with proinflammatory cytokine interleukin-22 (IL-22), the epidermal differentiation of Labskin, a living skin equivalent (LSE), successfully modeled psoriasis in vitro. Masson's trichrome staining enabled visualization and quantification of epidermal differentiation between the untreated and IL-22 treated psoriatic LSEs. Matrix-assisted laser desorption ionization mass spectrometry imaging was used to observe the spatial location of the psoriatic therapy drug acetretin following 48 h treatments within both psoriatic and normal LSEs. After 24 h, the drug was primarily located in the epidermal regions of both the psoriatic and nonpsoriatic LSE models whereas after 48 h it was detectible in the dermis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available